-
The FDA has approved a new drug for the treatment of gastrointestinal stromal tumor and metastatic renal cell cancer. Sunitinib is an orally active, highly selective, multi-targeted tyrosine kinase inhibitor. The drug was given a priority review and was approved in less than 6 months. Sunitinib is marketed by Pfizer as Sutent®.
-
Erectile Dysfunction and Subsequent Cardiovascular Disease; Oseltamivir Resistance during Influenza A Infection; Dietary Intake of Antioxidants and AMD
-
Although aspirin (ASA), particularly low-dose ASA 81 mg/d (LD-ASA), is well established as an appropriate agent for secondary prevention of cardiovascular disease, recent results from the Women's Health Study (WHS) about the impact of ASA in primary prevention came as a surprise...
-
A return to full normal activities, including work at 2 weeks, after AMI appears to be safe in patients who are stratified to a low-risk group.
-
The number of previous acute exacerbations of chronic bronchitis (AECBs) and the baseline FEV1 level are potent prognostic factors of the short- and long-term outcomes of AECB.
-
Itopride, a D2 dopamine agonist with anticholinesterase effects, was marginally superior to placebo in 'functional dyspepsia.'
-
Visual hallucinations, extrapyramidal motor signs, and visuoconstructional impairments at time of presentation are strongly suggestive of a diagnosis of dementia with Lewy bodies.
-
A novel T-cell inhibitor has been approved for the treatment of rheumatoid arthritis. Abatacept is the first selective modulator of a costimulatory signal involved in T-cell activation (costimulatory blocker).
-
There is a wide variation in the rate of coronary heart disease (CHD) in diabetes, depending on the population and existing risk factors.
-
The availability of a growing number of therapeutic options for acute stroke patients makes rapid and reliable diagnosis of stroke at the bedside more important than ever.
